BACKGROUND: In angioimmunoblastic T-cell lymphoma, symptoms linked to B-lymphocyte activation are common, and variable numbers of CD20(+) large B-blasts, often infected by Epstein-Barr virus, are found in tumor tissues. We postulated that the disruption of putative B-T interactions and/or depletion of the Epstein-Barr virus reservoir by an anti-CD20 monoclonal antibody (rituximab) could improve the clinical outcome produced by conventional chemotherapy. DESIGN AND METHODS: Twenty-five newly diagnosed patients were treated, in a phase II study, with eight cycles of rituximab + chemotherapy (R-CHOP21). Tumor infiltration, B-blasts and Epstein-Barr virus status in tumor tissue and peripheral blood were fully characterized at diagnosis and were correlated with clinical outcome. RESULTS: A complete response rate of 44% (95% CI, 24% to 65%) was observed. With a median follow-up of 24 months, the 2-year progression-free survival rate was 42% (95% CI, 22% to 61%) and overall survival rate was 62% (95% CI, 40% to 78%). The presence of Epstein-Barr virus DNA in peripheral blood mononuclear cells (14/21 patients) correlated with Epstein-Barr virus score in lymph nodes (P<0.004) and the detection of circulating tumor cells (P=0.0019). Despite peripheral Epstein-Barr virus clearance after treatment, the viral load at diagnosis (>100 copy/μg DNA) was associated with shorter progression-free survival (P=0.06). CONCLUSIONS: We report here the results of the first clinical trial targeting both the neoplastic T cells and the microenvironment-associated CD20(+) B lymphocytes in angioimmunoblastic T-cell lymphoma, showing no clear benefit of adding rituximab to conventional chemotherapy. A strong relationship, not previously described, between circulating Epstein-Barr virus and circulating tumor cells is highlighted.
BACKGROUND: In angioimmunoblastic T-cell lymphoma, symptoms linked to B-lymphocyte activation are common, and variable numbers of CD20(+) large B-blasts, often infected by Epstein-Barr virus, are found in tumor tissues. We postulated that the disruption of putative B-T interactions and/or depletion of the Epstein-Barr virus reservoir by an anti-CD20 monoclonal antibody (rituximab) could improve the clinical outcome produced by conventional chemotherapy. DESIGN AND METHODS: Twenty-five newly diagnosed patients were treated, in a phase II study, with eight cycles of rituximab + chemotherapy (R-CHOP21). Tumor infiltration, B-blasts and Epstein-Barr virus status in tumor tissue and peripheral blood were fully characterized at diagnosis and were correlated with clinical outcome. RESULTS: A complete response rate of 44% (95% CI, 24% to 65%) was observed. With a median follow-up of 24 months, the 2-year progression-free survival rate was 42% (95% CI, 22% to 61%) and overall survival rate was 62% (95% CI, 40% to 78%). The presence of Epstein-Barr virus DNA in peripheral blood mononuclear cells (14/21 patients) correlated with Epstein-Barr virus score in lymph nodes (P<0.004) and the detection of circulating tumor cells (P=0.0019). Despite peripheral Epstein-Barr virus clearance after treatment, the viral load at diagnosis (>100 copy/μg DNA) was associated with shorter progression-free survival (P=0.06). CONCLUSIONS: We report here the results of the first clinical trial targeting both the neoplastic T cells and the microenvironment-associated CD20(+) B lymphocytes in angioimmunoblastic T-cell lymphoma, showing no clear benefit of adding rituximab to conventional chemotherapy. A strong relationship, not previously described, between circulating Epstein-Barr virus and circulating tumor cells is highlighted.
Authors: P Amé-Thomas; J Le Priol; H Yssel; G Caron; C Pangault; R Jean; N Martin; T Marafioti; P Gaulard; T Lamy; T Fest; G Semana; K Tarte Journal: Leukemia Date: 2011-10-21 Impact factor: 11.528
Authors: Nathalie Mourad; Nicolas Mounier; Josette Brière; Emmanuel Raffoux; Alain Delmer; Alfred Feller; Chris J L M Meijer; Jean-François Emile; Réda Bouabdallah; André Bosly; Jacques Diebold; Corinne Haioun; Bertrand Coiffier; Christian Gisselbrecht; Philippe Gaulard Journal: Blood Date: 2008-02-21 Impact factor: 22.113
Authors: Yuanping Zhou; Ayoma D Attygalle; Shih-Sung Chuang; Tim Diss; Hongtao Ye; Hongxiang Liu; Rifat A Hamoudi; Philippa Munson; Chris M Bacon; Ahmet Dogan; Ming-Qing Du Journal: Br J Haematol Date: 2007-07 Impact factor: 6.998
Authors: Peter Reimer; Thomas Rüdiger; Eva Geissinger; Florian Weissinger; Christoph Nerl; Norbert Schmitz; Andreas Engert; Hermann Einsele; Hans Konrad Müller-Hermelink; Martin Wilhelm Journal: J Clin Oncol Date: 2008-11-24 Impact factor: 44.544
Authors: Nicolas Fazilleau; Linda Mark; Louise J McHeyzer-Williams; Michael G McHeyzer-Williams Journal: Immunity Date: 2009-03-20 Impact factor: 31.745
Authors: Kenneth R Carson; Steven M Horwitz; Lauren C Pinter-Brown; Steven T Rosen; Barbara Pro; Eric D Hsi; Massimo Federico; Christian Gisselbrecht; Marc Schwartz; Lisa A Bellm; Mark A Acosta; Andrei R Shustov; Ranjana H Advani; Tatyana A Feldman; Mary Jo Lechowicz; Sonali M Smith; Frederick Lansigan; Anil Tulpule; Michael D Craig; John P Greer; Brad S Kahl; Joseph W Leach; Neil Morganstein; Carla Casulo; Steven I Park; Francine M Foss Journal: Cancer Date: 2016-12-02 Impact factor: 6.860
Authors: Shweta Jain; Jing Chen; Alina Nicolae; Hongsheng Wang; Dong-Mi Shin; Elisabeth B Adkins; Thomas J Sproule; Caroline M Leeth; Tomomi Sakai; Alexander L Kovalchuk; Mark Raffeld; Jerrold M Ward; Jerold E Rehg; Thomas A Waldmann; Elaine S Jaffe; Derry C Roopenian; Herbert C Morse Journal: Am J Pathol Date: 2015-09-09 Impact factor: 4.307
Authors: Barbara Ottolini; Nadia Nawaz; Christopher S Trethewey; Sami Mamand; Rebecca L Allchin; Richard Dillon; Paul A Fields; Matthew J Ahearne; Simon D Wagner Journal: Blood Adv Date: 2020-06-09